查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844330

皮膚病藥物市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Dermatology Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球皮膚病藥物市場價值為 297 億美元，預計將以 10.1% 的複合年成長率成長，到 2034 年達到 769 億美元。

皮膚科藥物市場 - IMG1

這一上升趨勢的促進因素包括痤瘡、濕疹和牛皮癬等慢性和急性皮膚病的日益流行，以及人們對罕見皮膚病的日益關注。由於單株抗體和小分子抑制劑等標靶治療技術的進步，市場正呈現強勁成長勢頭，這些技術正在帶來更有效、更利於患者的治療結果。針對抗藥性皮膚病的治療需求也在不斷成長，這為旨在控制症狀和減緩病情進展的新劑型創造了空間。醫院、皮膚科診所和居家醫療服務可近性的持續擴大，持續推動了藥物的採用，尤其是在已開發地區和新興地區。病患意識的不斷提升，加上消費者對個人化醫療的偏好不斷變化，也正在推動藥物的成長。領先的製藥公司正在大力投資研發，以獲得監管部門的批准，並推出針對特定發炎或免疫途徑的療法。這些努力加強了向精準皮膚病學的轉變，並最佳化了給藥平台，旨在最大限度地減少副作用並提高患者的長期依從性。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 297億美元
預測值 769億美元
複合年成長率 10.1%

2024年，抗發炎療法市場佔32.6%的市場佔有率，預計到2034年將達到257億美元，複合年成長率為10.4%。皮質類固醇和非類固醇類藥物在治療多種發炎性皮膚病方面的高效性支撐了這一市場主導地位。這些製劑能夠快速緩解症狀，使其成為治療急性和慢性疾病的標準方法。隨著異位性皮膚炎和牛皮癬等皮膚病的發病率持續上升，這些藥物的應用也隨之增加，其中大多數已成為臨床實踐中的一線療法。

2024年，處方藥市場規模達212億美元。強力的臨床證據、持續的創新以及標靶品牌藥物的開發，為處方藥的持續應用提供了支持。這些療法對於治療中度至重度皮膚病至關重要，尤其是那些需要長期使用生物製劑、皮質類固醇和抗真菌藥物治療的皮膚病。監管部門的批准和配方的最佳化正在推動處方藥的市場滲透，尤其是在患者需要客製化、持續性醫療護理的領域。

2024年，北美皮膚科藥物市場佔據40.4%的市場佔有率，這得益於人們的認知度提高、先進醫療服務可及性的提升以及慢性皮膚病患者數量的增加。該地區的成長也受到個人化皮膚科治療（例如基於生物標記的藥物開發和基因分析）的推動。包括加拿大和美國在內的該地區各國正在完善其醫療保健框架，以改善皮膚科治療的可及性，並輔以優惠的報銷政策和公共衛生推廣計劃。

塑造全球皮膚科藥物產業格局的關鍵參與者包括高德美、輝瑞、因塞特、賽諾菲、禮來、阿斯特捷利康、艾伯維、葛蘭素史克、利奧製藥、博士倫、Dermavant Sciences、諾華、安進、強生、羅氏、Almirall 和默克。為了擴大市場佔有率，領先的皮膚科藥物製造商正在採取多管齊下的策略。許多公司正在投資下一代生物製劑和基因標靶療法，以豐富其產品組合併滿足不斷變化的治療需求。與生物技術公司和研究機構的策略合作有助於加速藥物發現和產品線開發。各公司也優先考慮地理擴張，尤其是進入醫療基礎設施日益完善的新興市場。

目錄

第1章：方法論與範圍

第 2 章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
    • 供應商格局
    • 每個階段的增值
    • 影響價值鏈的因素
  • 產業衝擊力
    • 成長動力
      • 慢性皮膚病盛行率不斷上升
      • 人口結構變化與生活方式因素
      • 生物製劑和小分子藥物的進展
      • 人們對皮膚健康和美學的認知不斷提高
    • 產業陷阱與挑戰
      • 不良反應和抗藥性
      • 資源匱乏環境下的取得受限
    • 市場機會
      • 個人化皮膚病學的擴展
      • 人工智慧與遠距醫療皮膚病學的整合
  • 成長潛力分析
  • 監管格局
    • 北美洲
    • 歐洲
    • 亞太地區
  • 未來市場趨勢
  • 技術格局
  • 投資和融資格局
  • 專利分析
  • 報銷場景
  • 管道分析
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
    • 全球的
    • 北美洲
    • 歐洲
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係與協作
    • 新產品發布
    • 擴張計劃

第5章：市場估計與預測：按藥物類別，2021 - 2034 年

  • 主要趨勢
  • 免疫調節劑
  • 類視黃醇
  • 抗生素
  • 抗發炎藥
  • 抗真菌藥物
  • 其他藥物類別

第6章：市場估計與預測：按適應症，2021 - 2034 年

  • 主要趨勢
  • 牛皮癬
  • 異位性皮膚炎
  • 粉刺
  • 皮膚癌
  • 其他適應症

第7章：市場估計與預測：按模式，2021 - 2034

  • 主要趨勢
  • 處方藥
  • 非處方藥

第8章：市場估計與預測：按年齡層，2021 - 2034 年

  • 主要趨勢
  • 兒科
  • 成年人
  • 老年

第9章：市場估計與預測：按管理路線，2021 - 2034 年

  • 主要趨勢
  • 腸外
  • 外用
  • 口服

第 10 章：市場估計與預測：依最終用途，2021 年至 2034 年

  • 主要趨勢
  • 醫院
  • 皮膚科診所
  • 居家照護環境
  • 其他最終用途

第 11 章：市場估計與預測：按地區，2021 年至 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 12 章：公司簡介

  • AbbVie
  • Almirall
  • Amgen
  • AstraZeneca
  • Bausch Health
  • Dermavant Sciences
  • Eli Lilly and Company
  • F. Hoffmann La Roche
  • Galderma
  • GlaxoSmithKline
  • Incyte
  • Johnson & Johnson
  • Leo Pharma
  • Merck KGaA
  • Novartis
  • Pfizer
  • Sanofi
簡介目錄
Product Code: 6311

The Global Dermatology Drugs Market was valued at USD 29.7 billion in 2024 and is estimated to grow at a CAGR of 10.1% to reach USD 76.9 billion by 2034.

Dermatology Drugs Market - IMG1

This upward trend is driven by the increasing prevalence of chronic and acute skin conditions such as acne, eczema, and psoriasis, along with a growing focus on rare dermatological disorders. The market is witnessing strong momentum due to technological advances in targeted therapies, including monoclonal antibodies and small molecule inhibitors, which are delivering more effective and patient-friendly outcomes. Demand is also rising for treatments addressing drug-resistant skin diseases, which is creating space for new formulations designed to control symptoms and slow disease progression. The expanding access to care across hospitals, dermatology clinics, and home-based healthcare continues to boost drug adoption, particularly in both developed and emerging regions. Rising patient awareness, coupled with evolving consumer preference for personalized medicine, is also shaping growth. Leading pharmaceutical players are investing heavily in R&D to secure regulatory approvals and launch therapies that act on specific inflammatory or immune pathways. These efforts have strengthened the shift toward precision dermatology and optimized drug delivery platforms aimed at minimizing side effects and improving long-term patient adherence.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$29.7 Billion
Forecast Value$76.9 Billion
CAGR10.1%

The anti-inflammatory therapies segment held a 32.6% share in 2024 and is projected to reach USD 25.7 billion by 2034, growing at a CAGR of 10.4%. This dominance is supported by the high efficacy of corticosteroids and non-steroidal agents in addressing a wide range of inflammatory skin disorders. These formulations offer quick relief, making them the standard approach in managing both acute and persistent conditions. As skin disorders such as atopic dermatitis and psoriasis continue to rise, the adoption of these medications increases, with most being first-line therapies in clinical practice.

The prescription drugs segment generated USD 21.2 billion in 2024. Their continued use is supported by strong clinical evidence, consistent innovation, and the development of targeted branded drugs. These therapies are central in managing moderate to severe skin conditions, especially those that require long-term treatment using biologics, corticosteroids, and antifungals. Regulatory approvals and enhanced formulations are fueling their market penetration, particularly in segments where patients require customized, ongoing medical care.

North America Dermatology Drugs Market held a 40.4% share in 2024, driven by high awareness levels, better access to advanced medical care, and an increasing number of individuals affected by chronic skin conditions. The region's growth is also being influenced by the adoption of personalized dermatological treatments, such as biomarker-based drug development and genetic profiling. Countries across the region, including Canada and the U.S., are enhancing their healthcare frameworks to improve dermatological access, aided by favorable reimbursement policies and public health outreach programs.

Key players shaping the landscape of the Global Dermatology Drugs Industry include Galderma, Pfizer, Incyte, Sanofi, Eli Lilly and Company, AstraZeneca, AbbVie, GlaxoSmithKline, Leo Pharma, Bausch Health, Dermavant Sciences, Novartis, Amgen, Johnson & Johnson, F. Hoffmann La Roche, Almirall, and Merck KGaA. To expand their presence, leading dermatology drug manufacturers are embracing multi-pronged strategies. Many are investing in next-generation biologics and gene-targeted therapies to diversify their portfolios and meet evolving treatment needs. Strategic collaborations with biotech firms and research institutions help accelerate drug discovery and pipeline development. Companies are also prioritizing geographic expansion, particularly into emerging markets with growing healthcare infrastructure.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumption and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Drug class trends
    • 2.2.3 Indication trends
    • 2.2.4 Mode trends
    • 2.2.5 Age group trends
    • 2.2.6 Route of administration
    • 2.2.7 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factor affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic skin conditions
      • 3.2.1.2 Demographic shifts and lifestyle factors
      • 3.2.1.3 Advancements in biologics and small molecule drugs
      • 3.2.1.4 Growing awareness of skin health and aesthetics
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Adverse effects and drug resistance
      • 3.2.2.2 Limited access in low-resource settings
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion of personalized dermatology
      • 3.2.3.2 Integration of AI and telehealth dermatology
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Future market trends
  • 3.6 Technological landscape
  • 3.7 Investment and funding landscape
  • 3.8 Patent analysis
  • 3.9 Reimbursement scenario
  • 3.10 Pipeline analysis
  • 3.11 Porter's analysis
  • 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Immunomodulators
  • 5.3 Retinoids
  • 5.4 Antibiotics
  • 5.5 Anti-inflammatory agents
  • 5.6 Antifungal drugs
  • 5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Psoriasis
  • 6.3 Atopic dermatitis
  • 6.4 Acne
  • 6.5 Skin cancer
  • 6.6 Other indications

Chapter 7 Market Estimates and Forecast, By Mode, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Prescription drugs
  • 7.3 Over the counter drugs

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Paediatric
  • 8.3 Adults
  • 8.4 Geriatric

Chapter 9 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 Parenteral
  • 9.3 Topical
  • 9.4 Oral

Chapter 10 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 10.1 Key trends
  • 10.2 Hospitals
  • 10.3 Dermatologist clinics
  • 10.4 Homecare settings
  • 10.5 Other end use

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 11.1 Key trends
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 France
    • 11.3.4 Spain
    • 11.3.5 Italy
    • 11.3.6 Netherlands
  • 11.4 Asia Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 South Korea
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Argentina
  • 11.6 Middle East and Africa
    • 11.6.1 South Africa
    • 11.6.2 Saudi Arabia
    • 11.6.3 UAE

Chapter 12 Company Profiles

  • 12.1 AbbVie
  • 12.2 Almirall
  • 12.3 Amgen
  • 12.4 AstraZeneca
  • 12.5 Bausch Health
  • 12.6 Dermavant Sciences
  • 12.7 Eli Lilly and Company
  • 12.8 F. Hoffmann La Roche
  • 12.9 Galderma
  • 12.10 GlaxoSmithKline
  • 12.11 Incyte
  • 12.12 Johnson & Johnson
  • 12.13 Leo Pharma
  • 12.14 Merck KGaA
  • 12.15 Novartis
  • 12.16 Pfizer
  • 12.17 Sanofi